Cancer-associated antigen analogue peptides and uses thereof
US8404803B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Mar 31, 2006 |
| Grant date | Mar 26, 2013 |
| Priority date | — |
| Expiry date | Aug 30, 2028 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
First, to solve the problems of the present invention, the present inventors confirmed the presence of ovarian cancer antigen-specific T cells in the peripheral blood of ovarian cancer patients by using an experimental system that detects combinations of CD4 and IL-4 or IFNγ. Next, using analogue peptides of the core protein MUC 16 of the ovarian cancer-associated antigen CA 125, the present inventors revealed that antigen-specific CD4-positive T cells are present at an average frequency of about 4% in the peripheral mononuclear cells of patients and healthy subjects. Then, the present inventors analyzed the epitope for T cells in the core protein MUC 16 of the ovarian cancer-associated antigen CA 125, and determined the amino acid sequence FTLNFTITN (SEQ ID NO: 1) to be a shorter epitope. The present inventors further discovered that the analogue peptide OVCA11: GHTAPGPLLVPFTLNFTITN (SEQ ID NO:11) is suitable for T cell activation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.